Chest Clinic, PGIMER
Chandigarh, 160012, India
NCT Number: NCT01908868
The investigators hypothesize that conventional or EBUS-TBNA will have equal efficiency in diagnosing sarcoidosis when performed in conjunction with endobronchial and transbronchial lung biopsy.
Looking for future studies?
Notify Me15 year–75 year
All sexes
Interventional
Not applicable
Chandigarh, 160012, India
Diagnostic procedures like transbronchial lung biopsy (TBLB), transbronchial needle aspiration (TBNA) and endobronchial biopsy (EBB) are routinely used to obtain pathological confirmation of pulmonary sarcoidosis. Real-time convex probe endobronchial ultrasound-guided TBNA (EBUS-TBNA) has shown immense potential, however it is costly, labor intensive and still has limited availability, especially in low and middle income countries. In the past, TBLB has been the bronchoscopic procedure of choice for diagnosis of sarcoidosis however currently its role is being debated with the advent of EBUS. We have observed that EBUS even though has high yield yet the optimal diagnosis is obtained only when combined with EBB and TBLB. The investigators hypothesize that conventional or EBUS-TBNA will have equal efficiency in diagnosing sarcoidosis when performed in conjunction with endobronchial and transbronchial lung biopsy.
The study compares the diagnostic yield of EBUS-TBNA (plus EBB and TBLB) vs. conventional TBNA (plus EBB and TBLB) for diagnosis of sarcoidosis.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Consecutive patients presenting with clinicoradiological features suggestive of sarcoidosis and an indication for transbronchial needle aspiration
Exclusion criteria
Mediastinal and hilar lymph node aspiration using endobronchial ultrasound
Mediastinal and hilar lymph node aspiration using blind transbronchial needle aspiration
Endobronchial and transbronchial lung biopsy using flexible bronchoscopy
Time frame: 18 months
The primary outcome is the diagnostic yield of the procedure defined as demonstration of granulomatous inflammation in two groups in patients finally labelled as sarcoidosis
Time frame: 18 months
Occurrence of serious adverse events (pneumothorax, bleeding >100 ml, death) in the two groups
Time frame: 18 months
To study the diagnostic yield of EBUS-TBNA, conventional TBNA, TBLB and EBB
Post Graduate Institute of Medical Education and Research, Chandigarh
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03814317
Cardiovascular Diseases, Hemic and Lymphatic Diseases
Gainesville, Florida, United States
View Trial DetailsNCT01610843
Hemic and Lymphatic Diseases, Hypersensitivity
Iowa City, Iowa, United States
View Trial DetailsNCT01687517
Hemic and Lymphatic Diseases, Hypersensitivity
Paris, France
View Trial DetailsNCT06907953
COVID-19, Chronic Disease
New York, United States
View Trial Details